TR200101895T2 - Cinsel rahatsızlıkların tedavisi. - Google Patents

Cinsel rahatsızlıkların tedavisi.

Info

Publication number
TR200101895T2
TR200101895T2 TR2001/01895T TR200101895T TR200101895T2 TR 200101895 T2 TR200101895 T2 TR 200101895T2 TR 2001/01895 T TR2001/01895 T TR 2001/01895T TR 200101895 T TR200101895 T TR 200101895T TR 200101895 T2 TR200101895 T2 TR 200101895T2
Authority
TR
Turkey
Prior art keywords
sexual
treatment
ailments
dose
compounds
Prior art date
Application number
TR2001/01895T
Other languages
English (en)
Inventor
Durham Meglasson Martin
B. Mccall Robert
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of TR200101895T2 publication Critical patent/TR200101895T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Abstract

Bu bulus, formül (A) ya sahip bilesikleri kullanarak, insanlarda cinsel rahatsizliklarin tedavi edilmesi ve insan olmayan memelilerde çiftlesmenin tesvik edilmesi ile ilgilidir: bu bilesikler, cinsel açidan terapötik miktar olarak yaklasik 0.2 - 8 mg/kisi/doz ve cinsel çiftlesme miktari olarak yaklasik 0.003-0.2 mg / kg / doz araliginda kullanilirlar.
TR2001/01895T 1999-01-06 1999-12-20 Cinsel rahatsızlıkların tedavisi. TR200101895T2 (tr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11484099P 1999-01-06 1999-01-06
US11505199P 1999-01-08 1999-01-08
US11592299P 1999-01-14 1999-01-14
US12054399P 1999-02-17 1999-02-17

Publications (1)

Publication Number Publication Date
TR200101895T2 true TR200101895T2 (tr) 2001-12-21

Family

ID=27493976

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01895T TR200101895T2 (tr) 1999-01-06 1999-12-20 Cinsel rahatsızlıkların tedavisi.

Country Status (20)

Country Link
US (9) US6455564B1 (tr)
EP (1) EP1140092A2 (tr)
JP (1) JP2002534376A (tr)
KR (1) KR20010089779A (tr)
CN (1) CN1332628A (tr)
AU (1) AU782596B2 (tr)
BR (1) BR9916759A (tr)
CA (1) CA2350946A1 (tr)
CO (1) CO5150156A1 (tr)
CZ (1) CZ20012459A3 (tr)
EA (2) EA005412B1 (tr)
HK (1) HK1041812A1 (tr)
HU (1) HUP0105036A3 (tr)
ID (1) ID30276A (tr)
IL (1) IL144172A0 (tr)
NZ (1) NZ512820A (tr)
PE (1) PE20001374A1 (tr)
SK (1) SK7732001A3 (tr)
TR (1) TR200101895T2 (tr)
WO (1) WO2000040226A2 (tr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
CA2358865A1 (en) * 1999-02-05 2000-08-10 Pharmacia & Upjohn Company Process to prepare (5r)-(methylamino)-5,6-dihydro-4h-imidazo[4,5,1-ij]-quinolin-2(1h)-one
EP1175204A4 (en) * 1999-05-04 2006-05-31 Aradigm Corp AEROSOL FORMULATION AND ARTICLES FOR INCREASING LIBIDO IN WOMEN BY MOMENTARY TESTOSTERONE ADMINISTRATION
US7258850B2 (en) 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
PT1593387E (pt) * 1999-06-23 2009-03-18 Pasteur Institut Composições para o tratamento de desordens comportamentais e deficiências interpessoais.
NZ531171A (en) 2000-04-21 2005-03-24 Upjohn Co Cabergoline-type compounds for treating fibromyalgia and chronic fatigue syndrome
AR033520A1 (es) * 2000-04-27 2003-12-26 Upjohn Co (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
US20030022912A1 (en) * 2001-02-08 2003-01-30 Martino Alice C. Rapid-onset medicament for treatment of sexual dysfunction
US20030073609A1 (en) 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
US7037257B1 (en) * 2002-08-22 2006-05-02 Koenig J Frank Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications
CA2500922A1 (en) * 2002-10-04 2004-04-22 Pharmacia Corporation Pharmaceutical compositions for treatment of parkinson's disease
EP1545521A2 (en) * 2002-10-04 2005-06-29 Pharmacia Corporation Compositions and methods for treating sexual dysfunction
JP2007504198A (ja) * 2003-09-05 2007-03-01 ノバルティス アクチエンゲゼルシャフト ベンゾ［ｇ］キノリン誘導体とプロスタグランジン誘導体を含む、組成物
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
WO2007016361A2 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
US7615075B2 (en) * 2005-11-04 2009-11-10 Rush University Medical Center Plastic implant impregnated with a degradation protector
US20080004310A1 (en) * 2006-06-19 2008-01-03 Applied Pharmacy Services, Inc. Lyophilized pharmaceutical composition
WO2017100324A1 (en) * 2015-12-10 2017-06-15 Repros Therapeutics Inc. Combination therapy for treating female hypoactive sexual desire disorders
EP3681885B1 (en) 2017-09-15 2024-02-28 Forma Therapeutics, Inc. Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
WO2020006483A1 (en) 2018-06-29 2020-01-02 Forma Therapeutics, Inc. Inhibiting creb binding protein (cbp)
BR112021016921A2 (pt) * 2019-03-15 2021-11-03 Forma Therapeutics Inc Inibição de proteína de ligação a elemento responsivo a amp cíclico (creb)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
EP4039746A1 (de) 2021-02-08 2022-08-10 Covestro Deutschland AG Polycarbonat-polyester zusammensetzung, formmasse und formkörper mit guter schlagzähigkeit und hoher thermischer belastbarkeit

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US4935514A (en) * 1989-06-06 1990-06-19 Ethyl Corporation Thiation process
ES2067744T3 (es) * 1989-06-09 1995-04-01 Upjohn Co Aminas heterociclicas con actividad sobre el sistema nervioso central.
US5273975A (en) * 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5541211A (en) 1991-06-18 1996-07-30 Orion-Yhtyma Oy Administration of atipamezole to elicit a yohimbine-like alpha-adrenoreceptor antagonistic noradrenergic transmission
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
NZ269018A (en) * 1993-07-27 1996-12-20 Upjohn Co 5-amino-5,6-dihydro-4h-imidazo[4,5,1-ij]-quinolin-2(1h)-one derivatives; pharmaceutical compositions
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
DE10199068I2 (de) 1994-04-22 2004-05-06 Pentech Pharmaceuticals Inc Sublinguale Dosierungsformen enthaltend apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion.
DE69720542D1 (de) * 1996-05-31 2003-05-08 Mochida Pharm Co Ltd PYRIDOCARBAZOL DERIVATE DIE EINEN cGMP-PDE INHIBILIERENDEN EFFEKT HABEN
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances

Also Published As

Publication number Publication date
CO5150156A1 (es) 2002-04-29
KR20010089779A (ko) 2001-10-08
US6890945B2 (en) 2005-05-10
US6921771B2 (en) 2005-07-26
PE20001374A1 (es) 2000-11-19
WO2000040226A2 (en) 2000-07-13
AU782596B2 (en) 2005-08-11
US6903127B2 (en) 2005-06-07
US20040214823A1 (en) 2004-10-28
EA200401256A1 (ru) 2005-12-29
AU2348200A (en) 2000-07-24
US20030013710A1 (en) 2003-01-16
SK7732001A3 (en) 2001-12-03
US20040214824A1 (en) 2004-10-28
EA200100750A1 (ru) 2001-12-24
JP2002534376A (ja) 2002-10-15
US20030004152A1 (en) 2003-01-02
NZ512820A (en) 2002-12-20
CA2350946A1 (en) 2000-07-13
US20040214825A1 (en) 2004-10-28
HUP0105036A3 (en) 2002-10-28
EP1140092A2 (en) 2001-10-10
BR9916759A (pt) 2001-09-25
US20020198187A1 (en) 2002-12-26
ID30276A (id) 2001-11-15
HUP0105036A2 (hu) 2002-05-29
WO2000040226A3 (en) 2001-02-01
CN1332628A (zh) 2002-01-23
CZ20012459A3 (cs) 2002-01-16
IL144172A0 (en) 2002-05-23
HK1041812A1 (zh) 2002-07-26
US20040214826A1 (en) 2004-10-28
US6809112B2 (en) 2004-10-26
US6455564B1 (en) 2002-09-24
EA005412B1 (ru) 2005-02-24
US20020107247A1 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
TR200101895T2 (tr) Cinsel rahatsızlıkların tedavisi.
DK0841949T3 (da) Anvendelse af saccharid-konjugater
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
DK1129093T3 (da) Pyrazolopyrimidinonderivater til behandling af impotens
TR200100172T2 (tr) Oral katı doz formunda eprosartan içeren biyolojik bakımdan kuvvetlendirilmiş formülasyonlar
EP1037673A4 (en) CHARGED LIPIDS AND THE USE THEREOF
CY1107615T1 (el) Θεραπευτικοι συνδυασμοι αντιυπερτασικων και αντιαγγειογενετικων παραγοντων
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
TNSN07208A1 (en) 3,5-DISUBTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
BR0115102A (pt) 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis como ligantes 5-hidroxitriptamina-6
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
MXPA02002249A (es) Composiciones farmaceuticas agradables al paladar para animales de compania.
ATE232396T1 (de) Oxydiertes thymosin beta 4
ATE355288T1 (de) Verbindungen und therapeutische methoden
TR200200066T2 (tr) Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri
TR200101719T2 (tr) Erkeklerde organik ereksiyona bağlı işlev bozukluğunun tedavisi için ilaç imalatında apomorfin kullanımı
TR199901104T2 (tr) Farmasötik bilesikler.
TR200800693T2 (tr) Miyelin kaybettiren hastalıkların ya da durumların tedavi yöntemi
AU6083301A (en) Treating eczema and/or psoriasis
TW200500079A (en) Compositions and methods for treating coronavirus infection and sars
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
AP9801202A0 (en) Atropisomers of 3-heteroaryl-4(3H)-quinazolinones.
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados